mfn-cus-pressmeddelanden

Nanologica to attend BIO-Europe 2019, Mar 25-27 in Vienne for partnering Discussions

Nanologica will be attending BIO-Europe Spring 2019 in Vienna, Mar. 25 – 27 to meet with potential pharmaceutical partners regarding co-development and licensing of NIC-001, Nanologica’s drug candidate for treating gastroparesis, as well as seeking partnership for further drug delivery applications using NLAB Silica™. Nanologica strives to be the world leader in nanoporous silica particles in its two business areas: Drug Delivery and Chromatography. Nanologica has developed a drug delivery platform based on its nanoporous

Read more »